NCT00345644View on ClinicalTrials.gov

Risedronate in Osteopenic Postmenopausal Women

PHASE3CompletedINTERVENTIONAL

Enrollment

156

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions

Osteoporosis

Interventions

DRUG

risedronate

risedronate sodium 35 mg tablets (once a week dose)

DRUG

risedronate placebo

placebo for risedronate tablets (once a week dose)

Trial Locations (1)

Unknown

Sanofi-Aventis, Paris

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Procter and Gamble

INDUSTRY

lead

Sanofi

INDUSTRY

NCT00345644 - Risedronate in Osteopenic Postmenopausal Women | Biotech Hunter | Biotech Hunter